Living Tumor Biopsies to Interrogate Immune Function and Response to Therapy

活体肿瘤活检以询问免疫功能和对治疗的反应

基本信息

批准号：
9135274
负责人：
MATTHEW F KRUMMEL
金额：
$ 19.73万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-01 至 2018-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9135274
关键词：
Antibody Therapy Beds Behavior Biological Assay Biopsy Biopsy Specimen Breast Color Combined Modality Therapy Complex Development Diagnostic Diagnostics Research Dose Formalin Future Glean Health Human ITGAM gene Image Image Analysis Immune Immune response Immune system In Situ Individual Life Lung Malignant Neoplasms Measures Medicine Methods Mus Myelogenous Nature Operative Surgical Procedures Pathology Patient Rights Patients Pattern Pharmaceutical Preparations Plant Roots Population Preparation Process Punch Biopsy Reader Reagent Resistance Route Sampling Selection for Treatments Series Skin Slice Staging Staining method Stains Stream T cell response T-Lymphocyte Technology Testing Therapeutic Time Tissues Variant Work blind cell motility cohort experience field study human disease immune function innovation mouse model novel novel therapeutics outcome forecast predicting response research study responders and non-responders response sample fixation spatiotemporal therapeutic development tumor tumor microenvironment two-photon

项目摘要

DESCRIPTION (provided by applicant): Treating the immune response within tumors is a major focus of new therapeutic development. For emerging therapies, there are clear responders and non-responders and at present, we are blind to knowing in how many ways the immune system is deficient. We are also unable to know which of the current or emerging therapies will work for a given patient. The current best-approach is to put each patient through a sequence of therapies before (hopefully) hitting upon one that works. In the future, we believe we will be able to tap the wealth of information that is contained in the just-excised biopsy of each patient. Each biopsy contains significantly more information than we currently glean in the form of the spatiotemporal cellular interactions that are taking place therein. Many immune activities continue to occur when biopsies are collected, maintained and imaged under appropriate conditions. We hypothesize that it is possible to study the functionality of the human tumor microenvironment `live' by the development of standard practices for `live biopsy'. If we are right, patient samples can be both characterized overall but also used as a test-bed for single or combinations of therapies to determine the most likely one to induce tumor rejection. Rare, small and information-rich human biospecimens will be directly and reproducibly studied and will be critical in next-gen discovery and diagnostic platforms. This study will define a serie of parameters by which biopsy samples can enter this important discovery stream.

描述（由申请人提供）：治疗肿瘤内的免疫反应是新疗法开发的主要焦点，对于新兴疗法来说，有明确的反应者和非反应者，目前我们不知道免疫系统有多少种方式。我们也无法知道哪种现有或新兴疗法对特定患者有效。目前的最佳方法是让每位患者接受一系列疗法，然后（希望）找到有效的疗法。未来，我们相信将能够利用每个患者刚刚切除的活检中包含的大量信息，其中包含的信息比我们目前以时空细胞相互作用的形式收集的信息要多得多。许多免疫活动仍在继续。当在适当的条件下收集、保存和成像活组织检查时，我们着迷的是，如果我们是对的，患者，通过制定“活体活检”标准实践，可以“活体”研究人类肿瘤微环境的功能。样品可以是两者总体上进行了表征，但也用作单一疗法或组合疗法的试验台，以确定最有可能诱导肿瘤排斥的罕见、小型且信息丰富的人类生物样本将被直接和可重复地研究，这对于下一代至关重要。这项研究将定义一系列参数，通过这些参数活检样本可以进入这一重要的发现流程。